Dara Biosciences (DARA) is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. This stock is trading up 15.2% to 92 cents per share in recent trading.
Today's Range: $0.86-$0.9852-Week Range: $0.62-$2.77 Volume: 2.5 million Three-Month Average Volume: 79,554 Shares of Dara Biosciences are exploding higher today after news broke that the Helsinn Group of Switzerland announced that it has entered into an exclusive agreement with Dara for U.S. commercial rights to Gelclair, an FDA-cleared product indicated for the treatment of oral mucositis. >>5 Oversold Stocks Ready to Bounce From a technical perspective, DARA is skyrocketing here with monster volume. This move has pushed DARA into breakout territory, since the stock has moved above some near-term overhead resistance levels at 84 to 85 cents per share. At last check, DARA has hit an intraday high of 98 cents and volume is well above its three-month average action of 79,554 shares. Traders should now look for long-biased trades in DARA once it triggers its next major breakout. That breakout will hit once DARA clears 98 cents and its 200-day moving average of $1.10 with high volume. Look for a sustained move or close above those levels with volume that's near or above 79,554 shares. If that breakout triggers soon, then DARA will have a great chance of re-testing or possibly taking out its next major overhead resistance level at $1.40.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV